|
Re: So many questions...
|
6
|
Resverlogix Corp.
|
Dec 07, 2019 10:20AM
|
|
Re: My latest email to IR
|
6
|
Resverlogix Corp.
|
Oct 18, 2017 12:54PM
|
|
RVX abstract for IDF 2015 World Diabetes Congress
|
6
|
Resverlogix Corp.
|
Nov 30, 2015 11:39AM
|
|
Re: Setting expectations....
|
6
|
Resverlogix Corp.
|
Jun 22, 2018 11:36AM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
6
|
Resverlogix Corp.
|
May 11, 2019 01:28PM
|
|
Re: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
|
6
|
Resverlogix Corp.
|
May 30, 2017 02:52PM
|
|
Renal trial delayed (again)
|
6
|
Resverlogix Corp.
|
Sep 27, 2017 10:19PM
|
|
Re: CVOTs on the Horizon
|
6
|
Resverlogix Corp.
|
Oct 01, 2018 05:48PM
|
|
Re: ... have you taken notice?...
|
6
|
Resverlogix Corp.
|
Apr 22, 2016 02:44PM
|
|
Re: Did DM show some cards?
|
6
|
Resverlogix Corp.
|
Sep 08, 2020 10:57AM
|
|
Standard of Care in BETonMACE
|
6
|
Resverlogix Corp.
|
Mar 19, 2019 08:45AM
|
|
Re: 3 ASN Kidney Conference Presentations Nov 8-9
|
6
|
Resverlogix Corp.
|
Nov 08, 2019 06:56PM
|
|
Re: Age, MoCA and CKD
|
6
|
Resverlogix Corp.
|
Nov 19, 2019 03:15PM
|
|
Re: ACC 2019 Abstracts
|
6
|
Resverlogix Corp.
|
Mar 21, 2019 03:10PM
|
|
Re: ZEN-3694 mCRPC Trial Status
|
6
|
Zenith Epigenetics
|
Nov 18, 2017 06:46PM
|
|
Toxicities observed with BET pan-inhibition by CPI-0610 and OTX-015
|
6
|
Zenith Epigenetics
|
Mar 24, 2016 11:13AM
|
|
American Heart Association abstract to be presented 11/15
|
6
|
Resverlogix Corp.
|
Nov 11, 2016 04:21PM
|
|
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
|
6
|
Zenith Epigenetics
|
May 10, 2022 12:08PM
|
|
Re: Naz listing?
|
6
|
Resverlogix Corp.
|
Apr 20, 2019 11:13AM
|
|
Re: Three Great Posts on Investor Village
|
6
|
Resverlogix Corp.
|
Oct 18, 2016 11:24AM
|
